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SUMMARY. Placental site trophoblastic tumor is the least common of gestational trophoblastic diseases. Its biologic
behavior is different from that of typical choriocarcinoma. Surgery is the cornerstone of therapy and the roles of chemothe-
rapy and radiation remain uncertain. We present a case of 24-year-old woman with placental site trophoblastic tumor and
nephrotic syndrome. There was no extrauterine spread which was determined by ultrasonography and computed tomography.
In attempt to preserve fertility, hysterotomy and tumor excision was performed.
Prikaz bolesnice
Klju~ne rije~i: tumor le`i{ta posteljice, nefroti~ki sindrom, dopler, NMR
SA`ETAK. Tumor le`i{ta posteljice (TLP) je najrje|i oblik trofoblasti~ne bolesti. Njegovo biolo{ko pona{anje je druga~ije
od onog u koriokarcinoma, variraju}i od dobro}udnog oblika do agresivne bolesti s fatalnim ishodom. Kirurgija – histerek-
tomija je lije~enje izbora, dok su rezultati kemoterapije i zra~enja dvojbeni. Prikazana je 24-godi{nja bolesnica s tumorom
le`i{ta posteljice i nefroti~kim sindromom. Ultrazvu~nim pregledom i kompjutoriziranom tomografijom nije na|eno izvan-
materni~no {irenje tumora te je, u cilju o~uvanja plodnosti, odstranjen samo tumor. Poslijeoperacijsko pra}enje bolesnice
u trajanju od godine dana nije pokazalo znakove recidiva bolesti.
Introduction
Placental site trophoblastic tumor (PSTT) is the least
common of gestational trophoblastic diseases (GTD).
Among 4988 patients with GTD Gillespie et al.1 found
only seven with PSTT. It was likely first described by
Marchand in 1895.2 In 1976 Kurman et al.3 described 12
patients with a variant of trophoblastic disease thought
to represent a distinct and exaggerated placental site re-
action. The lesion was designated trophoblastic pseudo-
tumor of the uterus to reflect the apparently benign na-
ture of the lesion. In 1981, Twiggs et al.4 reported the
death of a woman with a trophoblastic pseudotumor sec-
ondary to metastasis. Also in 1981, Scully and Young5
used the term »PSTT«, which they thought to be more
appropriate because of the malignant potential of the
tumor.
Its biologic behavior is different from that of typical
choriocarcinoma, ranging from a benign condition to an
aggressive disease with fatal outcome. Surgery is the
cornerstone of therapy and the roles of chemotherapy
and radiation remain uncertain. In the same time, main-
tenance of fertility is often an important concern for many
women with this tumor.
Case Report
A 24-year-old woman, gravida 1, para 1, presented in
October 1999 with vaginal spotting while continuing to
breast-feed her first child, who was born vaginally 9
months earlier. Prior to that, she had one episode of vag-
inal bleeding in Jully 1999. The result of pregnancy test
performed before she came to our institution was posi-
tive. On examination she was noted to be generally well
but hypertensive (160/100). At this visit, the pelvic ex-
amination revealed slightly enlarged, anterior, mobile
uterus with clear adnexa. The serum level of β-hCG was
204 IU/L. Transvaginal ultrasonography revealed thick-
ened endometrium and a 5.0×4.0 cm isoechogenic solid
mass just anterior to the uterine cavity (Fig. 1). The tumor
invaded myometrium till 5 mm from the serous layer.
The lesion was similar in appearance to an intramural
uterine leiomyoma. Suspicion of incomplete spontane-
ous abortion was established and on October 25, 1999
the patient underwent D&C. The curettage produced a
small amount of tissue without fetal parts, and pathologic
examination revealed only decidually transformed endo-
metrium.
The patient was discharged, but the repeated value of
serum β-hCG November 2, 1999 was 209 IU/L and on
November 10, 1999 was 275 IU/L. Suspicion of extrau-
terine pregnancy was established. The patient was ad-
mitted at our hospital again on November 17, 1999. Blood
pressure was 180/110 and the patient commenced an in-
tensive antihypertensive therapy. Repeated transvaginal
ultrasonography revealed previously described tumor and
a small amount of ascites in Douglas pouch. Color flow
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Doppler showed increased intratumoral vascularity, char-
acterised by abundant diastolic flow suggestive of low
vascular impedance (RI was 0.35) (Fig. 2). On Novem-
ber 18, 1999, the patient underwent diagnostic laparos-
copy. The intraoperative findings included enlarged uter-
us with tumor in the anterior wall, about 100 ccm of
ascites in Douglas pouch (cytologic finding was nega-
tive) and clear adnexa. Intraoperatively, D&C was repeat-
ed and pathologic examination revealed PSTT. The avera-
ge mitotic count was one mitotic figure per ten high-
-power fields, but in one active area four mitotic figures
were seen per ten high-power fields. Revision of the pre-
vious preparation also revealed PSTT!
Chest X ray and routine hematological indices were
normal. Special investigations showed normal renal and
Figure 1. Transvaginal ultrasound scan of placental site trophoblastic tumor.
Note: tumor invades myometrium till 5 mm from the serous layer
Slika 1. Transvaginalni ultrazvu~ni prikaz tumora le`i{ta posteljice. Pozor:
tumor prodire u miometrij 5 mm od seroze
Figure 2. Transvaginal color Doppler scan of intratumoral vessels. Blood
flow shows increased diastolic flow and low vascular resistance (RI=0.35)
Slika 2. Prikaz protoka krvi kroz tumorske krvne `ile transvaginalnim
doplerom u boji ukazuje na pove}ani dijastoli~ki protok i nizak krvno`ilni
otpor (RI=0,35)
Figure 3. Excised placental site trophoblastic tumor
Slika 3. Odstranjeni tumor le`i{ta posteljice
Figure 4. PSTT with uniform mononuclear intermediate trophoblast cells
infiltrating among fascicles of myometrial smooth muscle (hematoxylin-
-eosin stain, 200× magnification)
Slika 4. TLP s jednoli~nim stanicama intermedijalnog trofoblasta koje ura-
{taju izme|u snopova glatkog mi{i}ja miometrija (bojenje hematoksilin-
-eozinom, pove}anje 200×)
Figure 5. PSTT with polymorphic intermediate trophoblast cells. Besides
well-differentiated mononuclear cells some giant mononuclear and multi-
nuclear cells are observed (hematoxylin-eosin stain, 200× magnification)
Slika 5. TLP s raznolikim stanicama intermedijalnog trofoblasta. Pored
dobro diferenciranih mononuklearnih stanica vide se pojedina~ne divov-
ske mononuklearne i multinuklearne stanice (bojanje hematoksilin-eozi-
nom, pove}anje 200×)
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liver function. The serum albumin was low (24.5 g/L)
and total protein was 51 g/L. Urinary protein excretion
was elevated – 10.36 g per 24 hr. Serum cholesterol was
elevated (8.91 mmol/L) as well as triglycerides (2.20
mmol/L). The diagnosis of nephrotic syndrome was es-
tablished. β-hCG value on November 22, 1999 was 292
IU/L, three days later 241 IU/L, and four days thereafter
was 248 IU/L. A determination of serum human placen-
tal lactogen (hPL) was not technically possible. Compu-
terized tomography (CT) scan revealed enlarged uterus
with central areas of necrosis and hemorrhage. CT of the
brain, abdomen, and pelvis revealed no evidence of dis-
tant metastases.
The patient was counseled about the findings and the
disease process. She strongly desired preservation of fer-
tility. On December 1, 1999, the patient underwent explo-
ratory laparotomy, hysterotomy, and local excision of the
PSTT. General exploration of the abdomen was nega-
tive for extrauterine disease. On the anterior fundus the
tumor was clearly visible. A vertical anterior hysterotomy
Figure 6. PSTT stained by the indirect immunoperoxidase method for hPL
showing scattered positive cells (500× magnification)
Slika 6. TLP obojen indirektnom metodom imunoperoksidaze pokazuje
raspr{ene hPL pozitivne stanice (pove}anje 500×)
Figure 7. PSTT with hCG positive intermediate trophoblast cells (immu-
noperoxidase staining, 500× magnification)
Slika 7. TLP s hCG pozitivnim stanicama intermedijalnog trofoblasta (boje-
nje imunoperoksidazom, pove}anje 500×)
was made, and a tumor greater than 5,0 cm in diameter
was excised (Fig. 3). Then myometrium was reconstruct-
ed in layers.
Patho-histologic examination revealed a 5.5×4,5×4.5
cm PSTT that was somewhat circumscribed and infil-
trated the adjacent myometrium, with the areas of hem-
orrhage and necrosis on section. Histologic examination
revealed intermediate trophoblast infiltrating myometrial
fascicles and invading vessel walls, consistent with that
was seen at curettage. Most cells were mononuclear with
medium-sized nuclei (Fig. 4), but numerous giant mono-
nuclear and multinuclear cells were observed (Fig. 5).
In active areas eight mitotic figures were seen per ten
high-power fields. The surgical margins were not free of
tumor. Immunoperoxidase staining showed strong reac-
tivity with hPL (Fig. 6) and occasional staining with hCG
(Fig. 7).
Subsequently, the serum level of β-hCG on Decem-
ber 6, 1999 was 18.3, and on December 10, 1999 was
2.99. Repeated value of the serum albumin was 27.2 g/L
and total protein was 55 g/L. Urinary protein excretion
was significantly lower, 2.75 g per 24 hr. Repeated value
of serum cholesterol was 6.57 mmol/L. Hypertension was
mild, 150/100. From December 29, 1999 to January 4,
2000, she received single-agent chemotherapy (metho-
trexate 50 mg per day for four days and folinic acid 6
mg for two days).
On January 20, 2000 she was admitted to the depart-
ment because of following-up. Laboratory tests showed
normal values of the serum cholesterol – 4.06 mmol/L
and triglycerides – 0.87 mmol/L. The serum albumin was
slightly lower than normal – 39 g/L as well as a total
protein – 62 g/L. Urinary protein excretion was border-
line elevated – 0.43 g/24 h. The serum level of β-hCG
was not elevated. Blood pressure was normal. CT scan
of abdomen was negative for recurrent tumor. Magnetic
resonance imaging (MRI) study in February 2000 was
also negative for recurrent disease. To date, there has
been no evidence of tumor recurrence.
Discussion
Once believed to be a benign form of gestational tro-
phoblastic disease, PSTT is now known to be a malig-
nant and sometimes fatal tumor. The rarity of PSTT has
prevented agreement on staging, therapy, and imaging
appearance. Most authors have recommended hysterec-
tomy for treatment of PSTT. We have reported an ap-
proach to treatment of localized PSTT by hysterotomy,
excision, and uterine reconstruction in an attempt to pre-
serve fertility. There was no evidence of extrauterine
spread, which would be a contraindication for conserva-
tive management. The determination that the tumor was
localized was based on imaging studies (ultrasonogra-
phy, CT and chest X-ray). The assessment of localized
PSTT on the results of these imaging studies was con-
firmed intraoperatively.
The etiology, epidemiology, and risk factors for the
development of PSTT are not well understood. PSTT
88
Gynaecol Perinatol 2002;11(2):85–90 Vlatkovi} I. et al. Placental site trophoblastic tumor
typically occurs in women of childbearing age, with an
average age of occurring of 28 years. Only one case has
been described in a 53-year-old postmenopausal woman
who developed PSTT 18 years after her last document-
ed pregnancy.6 PSTT may develop after a normal preg-
nancy, an abortion, or a molar pregnancy. Presentation
may be from 1 week to 14 years after pregnancy.7 Ab-
normal vaginal bleeding is the most common presenta-
tion. Rare modes of presentation have included sponta-
neous uterine perforation and nephrotic syndrome.8
The PSTT is composed of intermediate trophoblast
(otherwise known as extravillous trophoblast or X cells),
a morphologically and functionally distinct trophoblastic
cell that predominates in the normal placental implanta-
tion site.7,9–11 An intermediate trophoblast is a distinctive
trophoblastic cell population from which four trophob-
lastic lesions are thought to arise: exaggerated placental
site (EPS), placental site nodule (PSN), placental site
trophoblastic tumor, and epitheloid trophoblastic tumor
(ETT).11 EPS and PSTT are related to the differentiation
of the intermediate trophoblast in the implantation site
(implantation site intermediate trophoblast), whereas
PSNs and ETTs are related to the intermediate trophoblast
of the chorion laeve (chorionic-type intermediate tropho-
blast). EPS and PSN are non-neoplastic lesions, whereas
PSTT and ETT are neoplasms with a potential for local
invasion and metastasis. PSTT lack the bilaminar struc-
ture of the trophoblast usually seen in choriocarcinoma
and consist of mononuclear cells with occasional giant
cells. Chorionic willi are only rarely detected. Necrosis
is common, but hemorrhage is much less common than
in typical choriocarcinoma. In PSTT, the intermediate
trophoblastic cells form a polypoid mass that may be
within the endometrial canal or the myometrium. Charac-
teristically the tumor invades the myometrium, dissect-
ing between individual muscle fibers. There is less vas-
cular invasion with PSTT and a greater propensity to
metastasize via lymphatics. However, there is a peculiar
behavior towards the uterine vasculature as spiral arter-
ies are dilated and transformed the same way as occurs
at the site of physiological implantation of pregnancy.12
The tumor is usually confined to the uterine corpus but
may metastasize to lung, liver, lymph nodes, brain, or
other organs and about 10% of patients die of uncon-
trolled metastases. Metastasis can occur years after diag-
nosis.
The variable and often low level of hCG detected in
these tumors reflects the lack of syncytiotrophoblast. The
levels of hCG are not an accurate indication of tumor
burden and cannot be used as a reliable tumor marker.
Most of the cells of PSTT contain HPL and a minority
contain hCG.9 In approximately 15% of PSTTs, hCG is
predominantly secreted or there is an equal distribution
of hCG and HPL.9 It has been suggested that tumors that
secrete predominantly hCG have a greater resemblance
to choriocarcinoma and it is possible that this group rep-
resents the more agressive PSTTs.9 This has not been
tested prospectively.
The clinical behavior may be extremely aggressive,
with nephrotic syndrome being a rare form of presenta-
tion. Nephrotic syndrome is characterized by albuminu-
ria, hypoalbuminemia, hyperlipidemia, and edema.13 The
syndrome is the result of excessive glomerular permea-
bility to plasma proteins and heavy proteinuria is a prime
characteristic. The pathogenesis is unknown, but may
be due to damage caused by the deposition of immune
complexes stimulated by the tumor. A distinctive glomer-
ular lesion has been described.14 In our case the excision
of tumor appears to have »cured« the nephrotic syn-
drome.
Only about 10% of PSTT are malignant, as defined
by the presence of metastatic disease.15 A well-defined
indicator for malignant behavior has not been determined.
A subset of patients with PSTT at high risk for metastases
has been defined on the basis of a mitotic count greater
than two mitoses per ten high-power fields.5,16 Because
of the rarity of the tumor, this definition of malignant
behavior is based on limited clinical experience. The
predictive value of this indicator is questionable because
of reports of metastatic PSTT with mitotic counts less
than two per ten high-power fields,15,17 and of localized
tumor with a mitotic count greater than ten per ten high-
-power fields.16 In addition, mitotic counts in the curet-
tage specimen may differ from those in the hysterectomy
specimen and from those in the resected metastasis.18
According to different authors,17,19,20 the long interval
from the antecedent pregnancy to clinical presentation
is a major adverse prognostic variable, and the outcome
in patients whose last known pregnancy was >2 years
prior to presentation with PSTT is poor. In the study of
Chang et al,21 patients with metastatic diseases were 3
years older than patients with diseases confined to the
uterus and had a higher incidence of term delivery as
their antecedent pregnancy.
Ultrasonography has become the preferred noninva-
sive diagnostic imaging modality that enables early con-
firmation of gestational trophoblastic disease. Findings
associated with PSTT comprise a variety of imaging pres-
entations.22–24 It can be a solid mass with cystic lesions
that correspond to dilated blood vessels22 or central he-
morrhagic areas23 or a solid tumor similar in appearance
to an intramural leiomyoma24 as it was in our patient.
Doppler studies of PSTT showed different types of tu-
moral vascularity – from low blood flow with high vas-
cular indices24 to abundant blood flow suggestive of low
vascular impedance25,26 as it was present in our case. Such
hypervascularity is a consequence of trophoblastic inva-
sion into the wall of arteries, a process which is physio-
logical in early pregnancy and results in transformation
of spiral arteries into dilated tortuos vascular channels.27
The reason that prominent vascular structures are seen
in some cases and not in others is unknown. As yet, there
have not been any data which clearly link death and re-
currence to size or vascularity of the primary tumor.
CT and MRI findings are also not specific. MR imag-
ing can reveal the site, size, prominent vascularity and
extent of PSTT and may reveal the presence of such tu-
mors that are not seen on sonography.28 Currently, no
imaging study is able to demonstrate microscopic me-
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tastases, but in a case in which microscopic nodal me-
tastasis was confirmed pathologically, preoperative im-
aging tests showed extensive uterine tumor.29
In the past, PSTT was cured in many patients by uter-
ine curettage, consistent with benign behavior of the tu-
mor.3,16 However, because of concern about potential
malignant behavior, for patients with the disease local-
ized to the uterus the treatment of choice is hysterecto-
my16,19 followed by adjuvant chemotherapy in selected
cases, depending on how certain the surgeon and pathol-
ogist are that the disease has been completely resected.19
This may represent overtreatment for most patients who
have benign tumors, and it does not preserve fertility in
women who may not be ready to forgo childbearing. We,
and some other authors28–30 suggest that preoperative
imaging may be used to define those patients with local-
ized PSTT who are candidates for conservative resec-
tion when preservation of fertility is a concern. In pa-
tients presenting with locally bulky disease or minimal-
ly metastatic disease, some authors19 recommend cytore-
duction with the EP (etoposide, paclitaxel), EMA (etopo-
side, methotrexate, actinomycin D) schedule prior to
debulking the disease by hysterectomy if the disease has
responded satisfactorily to the chemotherapy. The treat-
ment of PSTT considering expansion of the disease is
shown in Table 1. Because of the rarity of these tumors,
involvement of a gynecologic oncologist in the clinical
management of these patients is encouraged. While sur-
gery remains the most important therapeutic option for
the primary and metastatic lesions, chemotherapy and
radiation should be considered in metastatic disease.
Unlike choriocarcinoma, PSTT is relatively insensitive
to chemotherapy. Chemotherapy has developed over the
20 years since 1975. A few cases received chemotherapy
Table 1. Criteria for treatment of placental site trophoblastic tumor (modi-
fied from Newlands et al)18
Tablica 1. Kriteriji pri lije~enju tumora le`i{ta posteljice (sa~injeno prema
Newlands et al)18
Criteria – Kriteriji Treatment – Lije~enje
Localized disease Hysterectomy + adjuvant
Lokalizirana bolest chemotherapy (EMA/CO or EP/EMA) if
disease is not completely resected
Histerektomija + adjuvantna
kemoterapija (EMA/CO ili EP/EMA)
ukoliko tumor nije u potpunosti
odstranjen
Localized disease, but Tumor excision + adjuvant
patient desires preservation chemotherapy if disease is not
of fertility completely resected
Lokalizirana bolest, ali Odstranjenje tumora + adjuvantna
bolesnica `eli sa~uvati kemoterapija ukoliko tumor nije
plodnost u potpunosti odstranjen
Locally bulky disease Chemotherapy (EMA/CO or EP/EMA)
or minimally metastatic + hysterectomy
disease
Lokalna opse`na bolest Kemoterapija (EMA/CO ili EP/EMA)
ili minimalna metastatska + histerektomija
bolest
Metastatic disease Chemotherapy (EMA/CO or EP/EMA)
+ surgery
Metastatska bolest Kemoterapija (EMA/CO ili EP/EMA)
+ kirurgija
with simple schedules, such as methotrexate and folinic
acid, or actinomycin D or vincristine and cyclophospha-
mide. However, the greatest experience has been with
the EMA (etoposide, methotrexate, actinomycin D), CO
(cyclophosphamide/vincristine), and patients with met-
astatic disease should be started on that schedule. From
the limited data,19 cisplatinum should be introduced into
the chemotherapy schedule from the outset in a sched-
ule such as EP (etoposide, paclitaxel), EMA (etoposide,
methotrexate, actinomycin D). However, the activity of
new anticancer agents, such as the taxanes (paclitaxel
and docetaxel) and campothecines (topotecan and iri-
notecan), needs to be assessed in this disease, which can
become very resistant to previously available chemother-
apy.
Radiation is most useful in the setting of localized and
isolated recurrences.
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